Surgical Oncology Surgery

Lenvatinib vs sorafenib as second-line therapy after ATE+BEV failure in advanced hepatocellular carcinoma: A meta-analysis

Elsevier ·

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →